Misunderstandings, Misperceptions, and Mistakes in the Management of the Inflammatory Myopathies

John T. Kissel

doi:10.1055/s-2002-33047

Seminars in Neurology, Inhaltsverzeichnis

Semin Neurol 2002; 22(1): 041-052
DOI: 10.1055/s-2002-33047

Misunderstandings, Misperceptions, and Mistakes in the Management of the Inflammatory Myopathies

John T. Kissel

Professor and Vice-Chair, Department of Neurology, Ohio State University, Columbus, Ohio

Abstract

ABSTRACT

Many misconceptions persist concerning fundamental issues related to the idiopathic inflammatory myopathies. Such misconceptions can lead to frank mistakes in the diagnosis and management of these disorders. In some cases, these misperceptions have resulted from overreliance on out-of-date information and ``classic'' articles that are no longer classic! In other instances, misperceptions persist because of the many voids in our understanding of these diseases. This review uses case presentations to highlight important caveats in diagnosing and managing the common idiopathic inflammatory myopathies.

KEYWORDS

Polymyositis - dermatomyositis - inclusion body myositis - immunotherapy

Volltext

Referenzen

REFERENCES

1 Nash S M, Kissel J T. Inflammatory myopathies. In: Pourmand R, ed. Neuromuscular Diseases: Expert Clinicians Views Woburn: Butterworth-Heinemann 2001 0: 199-226
2 Dalakas M C, Karpati G. Inflammatory myopathies. In: Karpati G, Hilton-Jones D, Griggs RC, eds. Disorders of Voluntary Muscle Cambridge: Cambridge University Press 2001 0: 349-373
3 Bronner I M, van der Meulen F G M, Hoogendijk J. Polymyositis: a disease entity disputed. Neurology . 2002; 58 A389
4 Yazici Y, Kagen L J. The association of malignancy with myositis. Curr Op Rheumatol . 2000; 12 498-500
5 Hill C L, Zhang Y, Sigurgeirsson B. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet . 2001; 357 96-100
6 Buchbinder R, Forbes A, Hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Int Med . 2001; 134 1087-1095
7 Targoff I N. Update on myositis-specific and myositis-associated autoantibodies. Curr Op Rheumatol . 2000; 12 475-481
8 Chad D A. Inflammatory myopathies. In: Katirji B, Kaminski HJ, Preston DC, et al, eds. Neuromuscular Disorders in Clinical Practice {{ERR}}Boston: Butterworth-Heinemann; 2002: 1169-1180
9 Arahata K, Ishihara T, Fukunaga H. Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): immunocytochemical and genetic analyses. Muscle Nerve . 1995; 2 S56-66
10 Kissel J T, Lynn J, Rammohan K W. Mononuclear cell analysis of muscle biopsies in prednisone- and azathioprine-treated Duchenne muscular dystrophy. Neurology . 1993; 43 532-536
11 Kissel J T, Burrow K L, Rammohan K W, Mendell J T, and the CIDD Study Group. Mononuclear cell analysis of muscle biopsies in prednisone-treated and untreated Duchenne muscular dystrophy. Neurology . 1991; 41 667-672
12 Kissel J T. Facioscapulohumeral muscular dystrophy. Sem Neurol . 1999; 19 35-43
13 Maselli R A, Richman D P, Wollmann R L. Inflammation at the neuromuscular junction in myasthenia gravis. Neurology . 1991; 41 1497-1504
14 McNally E M, Ly C T, Rosenmann H. Splicing mutation in dysferlin produces limb-girdle muscular dystrophy with inflammation. Am J Med Gen . 2000; 91 305-312
15 Di Blasi C, Mora M, Pareyson D. Partial laminin alpha2 chain deficiency in a patient with myopathy resembling inclusion body myositis. Ann Neurol . 2000; 47 811-816
16 Bohan A, Peter J B. Polymyositis and dermatomyositis. N Engl J Med . 1975; 292 344-407
17 Oddis C V. Current approach to the treatment of polymyositis and dermatomyositis. Curr Op Rheumatol . 2000; 12 492-497
18 Anonymous. 64th ENMC International workshop: therapeutic approaches to dermatomyositis, polymyositis, and inclusion body myositis. Neuromuscular Disorders . 2001; 11 88-92
19 Ghate J, Katsambas A, Augerinouw G, Jorizzo J L. A therapeutic update on dermatomyositis/polymyositis. Int J Dermatol . 2000; 39 8187
20 Callen J P. Dermatomyositis. Lancet . 2000; 355 53-57
21 Rose M R, Kissel J T, Bickley L S, Griggs R C. Sustained myoglobinuria: the presenting manifestation of dermatomyositis. Neurology . 1996; 47 119-123
22 Cosnes A, Amaudric F, Gherardi R. Dermatomyositis without muscle weakness. Long-term follow-up of 12 patients without systemic corticosteroids. Arch Dermatol . 1995; 131 1381-1385
23 Kissel J T, Halterman R K, Rammohan K W, Mendell J R. The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis. Arch Neurol . 1991; 48 26-30
24 Kissel J T, Mendell J R, Rammohan K W. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med . 1986; 314 329-334
25 Dalakas M C, Illa I, Dambrosia J M. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med . 1993; 329 1993-2000
26 Vencovsky J, Jarosova K, Machacek S. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol . 2000; 29 95-102
27 Miller F W, Leitman S F, Cronin M E. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med . 1992; 326 1380-1384
28 Levine T D. B cell depletion chemotherapy with Rituxamab for dermatomyositis. Neurology . 2002; 58 A490
29 Boumpas D T, Chrousos G P, Wilder R L, Cupps T R, Balow J E. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Int Med . 1993; 119 1198-1208
30 Coutlakis P, Buckley L M. Glucocorticoid-induced osteoporosis: prevention and treatment. Bull Rheumatic Dis . 2000; 49 4:1-4
31 Alexanerson H, Stenstrom C H, Jenner G, Lundberg I. The safety of a restrictive home exercise program in patients with recent onset active polymyositis or dermatomyositis. Scand J Rheumatol . 2000; 29 295-301
32 Badrising U A, Maat-Schieman M, van Duinen G S. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology . 2000; 55 1385-1387
33 Amato A A, Gronseth G S, Jackson C E. Inclusion body myositis: clinical and pathological boundaries. Ann Neurol . 1996; 40 581-586
34 Barohn R J, Amato A A. Inclusion body myositis. Curr Treat Opt Neurol . 2000; 2 7-11
35 Peng A, Koffman B M, Malley J D, Dalakas M C. Disease progression in sporadic inclusion body myositis: observations in 78 patients. Neurology . 2000; 55 296-298
36 Hermanns B, Molnar M, Schroder J M. Peripheral neuropathy associated with hereditary and sporadic inclusion body myositis: confirmation by electron microscopy and morphometry. J Neurol Sci . 2000; 179 92-102
37 Van der Merulen F M, Hoogendijk J E, Moons K G, Veldman H, Badrising U A, Wokke J H. Rimmed vacuoles and the added value of SMI-31 staining in diagnosing sporadic inclusion body myositis. Neuromusc Dis . 2001; 11 447-451
38 Pruitt 2nd N J, Showalter C J, Engel A G. Sporadic inclusion body myositis: counts of different types of abnormal fibers. Ann Neurol . 1996; 39 139-143
39 Amemiya K, Granger R P, Dalakas M C. Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. Studies in repeated muscle biopsies. Brain . 2000; 123 2030-2039
40 Askanas V, Engel W K. Inclusion-body myositis: newest concepts of pathogenesis and relation to aging and Alzheimer disease. J Neuropathol Exp Neurol . 2001; 60 1-14
41 Banwell B L, Engel A G. AlphaB-crystallin immunolocalization yields new insights into inclusion body myositis. Neurology . 2000; 54 1033-1041
42 Griggs R C, Askanas V, DiMauro S. Inclusion body myositis and myopathies. Ann Neurol . 1995; 38 705-713
43 Dalakas M C, Sekul E A, Cupler E J, Sivakumar K. The efficacy of high-dose intravenous immunoglobulin (IVIg) in patients with inclusion-body myositis. Neurology . 1997; 48 712-716
44 Walter M C, Lochmuller H, Toepfer M. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol . 2000; 247 22-28
45 Dalakas M C, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology . 2001; 56 323-327
46 Spector S A, Lemmer J T, Koffman B M. Safety and efficacy of strength training in patients with inclusion body myositis. Muscle & Nerve . 1997; 20 1242-1248